# Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine

> **NCT02813486** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Green Cross Corporation** · enrollment: 220 (estimated)

## Conditions studied

- Tetanus
- Diphtheria
- Whooping Cough

## Interventions

- **BIOLOGICAL:** Biological: GC3111 vaccine
- **BIOLOGICAL:** Biological: Boostrix® vaccine

## Key facts

- **NCT ID:** NCT02813486
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2016-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02813486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02813486, "Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02813486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*